October 2, 2022

Volume XII, Number 275

2020 Business of Personalized Medicine Summit: Break Through to Solutions in the Birthplace of Biotechnology

How are businesses across the health care and life sciences spectrum collaborating to capitalize on the commercial promise of personalized medicine? Find out at the 2020 Business of Personalized Medicine Summit — join us at Oyster Point in South San Francisco on Thursday, February 27th!

Since the completion of the Human Genome Project in 2003, the genomic revolution has spurred immeasurable excitement and support surrounding the promise of personalized medicine, setting high expectations for a new era of health care and rapidly transforming the field into a multi-billion dollar industry.

While realizing the medical and commercial potential of personalized medicine has turned out to be neither quick nor easy, we could finally be on the cusp of widespread clinical adoption and improved patient outcomes thanks to recent advances with CRISPR gene editing and targeted therapies as well as the digital transformation of the industry. In fact, in its latest report, Cancer Statistics, 2020, the American Cancer Society cites a 2.2% drop in the U.S. cancer death rate from 2016 to 2017 — the largest single-year drop ever recorded — and attributes it largely to the development of targeted therapies and other personalized medicines for the treatment of lung and skin cancers.

With this welcome news underscoring the real medical contributions of personalized medicine, this year’s Summit aims to explore whether the business community might also be on the verge of capitalizing on the field’s commercial promise and, if so, what that could mean for innovation, investment, profitability, and growth in the space moving forward.

You won’t want to miss these one-of-a-kind discussions with key industry executives in the birthplace of biotechnology — REGISTER TO ATTEND TODAY!

Registration is complimentary for life sciences and health care executives, entrepreneurs, investors, and academics. For more information, visit www.personalizedmedicinesummit.com.

Featured Discussion Topics



 The capital raising landscape and lessons learned


 Spotlight on gene and cell therapy as an innovative and evolving technology area

 DTC Genetic Testing

 Capitalizing on the commercial potential of direct-to-consumer genetic testing


 Strategies for operationalizing a personalized medicine program at the point of care

 Connected Dots

 The promise behind AI for discovery, validation, diagnosis, and data sharing

 Companion Diagnostics

 Evolving business models for companion diagnostics

Confirmed Speakers

Lisa Alderson
Co-Founder and Chief Executive Officer, Genome Medical, Inc.

Kathleen Barnes, PhD
Director, Colorado Center for Personalized Medicine

Professor and Head, Division of Biomedical Informatics and Personalized Medicine, Department of Medicine, University of Colorado Anschutz Medical Campus

Paul Billings, MD, PhD
Chief Medical Officer and Senior Vice President, Medical Affairs, Natera

Anita Chawla, PhD
Managing Principal, Analysis Group

Curt Creely
Partner, Foley & Lardner LLP

Nicholas Dracopoli, PhD
Chief Scientific Officer, Delfi Diagnostics


Kyle Faget
Of Counsel, Foley & Lardner LLP

Matt Gardner
Founder and Chief Executive Officer, California Technology Council

Taha Jangda
Partner, HealthX Ventures

Christine Meda
Chief Business Officer, IncellDx

Nick Naclerio, PhD
Founding Partner, Illumina Ventures

Jonathan Norris
Managing Director of Sales Origination, Silicon Valley Bank

Kathryn Phillips, PhD
Founding Director, UCSF Center for Translational and Policy Research on Personalized Medicine (TRANSPERS)

Professor of Health Services Research and Health Economics, Department of Clinical Pharmacy, UCSF School of Pharmacy


Bruce Quinn, MD, PhD
Principal, Bruce Quinn Associates LLC

Hakan Sakul, PhD
Vice President and Head of Diagnostics, Pfizer Inc.

Robin Smith
Founder and Chief Executive Officer, Orig3n

Judy Waltz
Partner, Foley & Lardner LLP

Emily Weber
Partner, Foley & Lardner LLP

Frank Witney
Operating Partner, Ampersand Capital Partners

Carol Yarbrough
Business Operations Manager, Telehealth Resource Center, UCSF Medical Center

About the BPM Summit

Since 2013, Foley & Lardner LLP has collaborated with a multidisciplinary Advisory Board comprised of industry executives to host this one-day thought leadership forum addressing the future of health economics as well as the impact to businesses stemming from personalized medicine’s growing support. The event brings together stakeholders from financial entities, life sciences companies, care providers, and research and policy organizations to discuss critical insights and solutions for product development, commercialization, and mainstream implementation at the point of care.

What Makes the BPM Summit Unique?

Many forums for discussing personalized medicine focus on specialized areas such as underlying technologies, financing, regulatory pathways, or payment issues. The BPM Summit attempts to address cross-sections of such issues with a clear eye towards modeling successful and sustainable business models for entities already engaged in personalized medicine as well as those that seek to enter the space. The BPM Summit aims to set itself apart from other programs by focusing on the business challenges, trends, and opportunities within the personalized medicine marketplace while keeping in mind the potential implications for R&D and healthcare delivery.